WT1 Peptid Vaccination in Carcinomas
Phase 2
- Conditions
- WT1 Expressing Carcinoma
- Registration Number
- NCT00153608
- Lead Sponsor
- Charite University, Berlin, Germany
- Brief Summary
In this trial HLA-A2+ patients with WT1 expressing carcinomas are vaccinated with a peptide from the leukemia associated antigen WT1 together with immunological adjuvants KLH as T-helper protein and GM-CSF
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
- Metastatic cancer, no standard treatment option
- Resected cancer with minimal residual disease, no standard treatment option
- WT-1 expression
- HLA-A2
Exclusion Criteria
- Concurrent chemotherapy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Clinical efficacy
- Secondary Outcome Measures
Name Time Method Immune response Safety
Trial Locations
- Locations (1)
Hem&Onc Charité CBF
🇩🇪Berlin, Germany